Current Report Filing (8-k)
May 03 2022 - 7:46AM
Edgar (US Regulatory)
0001597264
false
0001597264
2022-05-03
2022-05-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event
Reported): May 3, 2022
Blueprint Medicines Corporation
(Exact name of registrant as specified in its charter)
Delaware |
|
001-37359 |
|
26-3632015 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification No.) |
45 Sidney Street
Cambridge, Massachusetts |
|
02139 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone
number, including area code: (617) 374-7580
(Former name or former address,
if changed since last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨ | Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425) |
|
¨ | Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12) |
|
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company ¨
If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Securities registered pursuant to Section 12(b) of
the Exchange Act:
Title of each class |
Trading symbol(s) |
Name of each exchange on which registered |
Common stock, par value $0.001 per share |
BPMC |
Nasdaq Global Select Market |
Item 2.02 Results of Operations and Financial Condition.
On May 3, 2022, Blueprint
Medicines Corporation announced its financial results for the quarter ended March 31, 2022 and other business highlights. The full text
of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated by reference herein.
The information in this
Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to
the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended,
or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits.
The following exhibit relating to Item 2.02 of
this Form 8-K shall be deemed to be furnished and not filed:
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
BLUEPRINT MEDICINES CORPORATION |
|
|
Date: May 3, 2022 |
By: |
/s/ Kathryn Haviland |
|
|
Kathryn Haviland |
|
|
Chief Executive Officer |
Blueprint Medicines (NASDAQ:BPMC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Blueprint Medicines (NASDAQ:BPMC)
Historical Stock Chart
From Sep 2023 to Sep 2024